AAPS PharmSciTech

, Volume 19, Issue 8, pp 3661–3669 | Cite as

Formulation, Characterization, and Pharmacokinetic Studies of 6-Gingerol-Loaded Nanostructured Lipid Carriers

  • Qiuyu Wei
  • Qiuxuan Yang
  • Qilong Wang
  • Congyong Sun
  • Yuan Zhu
  • Ya Niu
  • Jiangnan YuEmail author
  • Ximing XuEmail author
Research Article Theme: Lipid-Based Drug Delivery Strategies for Oral Drug Delivery
Part of the following topical collections:
  1. Theme: Lipid-Based Drug Delivery Strategies for Oral Drug Delivery


In this study, an optimized nanostructured lipid carriers (NLCs) were developed and investigated for improving the solubility and oral availability of 6-Gingerol (6G), an active and abundant component of ginger with limited applications due to its poor water solubility plus oral biological availability. The NLCs consisted of a solid lipid (glyceryl monostearate), another liquid lipid (decanoyl/octanoyl-glycerides) and mixed surfactants (Tween 80 and Poloxamer 188), and was prepared by high pressure homogenization method. The optimal 6G-NLC formulation was evaluated through physical properties such as appearance, mean particle size, zeta potential, encapsulation efficiency, and in vitro drug release, alongside techniques viz., transmission electron microscopy (TEM), differential scanning calorimetry (DSC), as well as powder X-ray diffraction (XRD). Pharmacokinetics were also evaluated in rats. The 6G-NLCs prepared with optimal formulation exhibited a homogenous spherical shape with mean particle size and zeta potential of 63.59 ± 5.54 nm and − 12.18 ± 1.06 mV. Encapsulation efficiency and drug loading were 76.71 ± 1.11 and 1.17 ± 0.35%, respectively. In vitro release profile of 6G from NLCs was sustained and fitted with Weibull equation. After oral administration of the 6G-NLCs, drug concentrations in serum, MRT, and AUC0-t were significantly higher as compared with the free 6G suspension. All these results indicated that the developed NLC formulation could be effective and promising drug carriers to improve the water solubility of 6G while sustaining the drug release as well as prolonging in vivo acting time of the drug coupled with oral bioavailability enhancement.


6-Gingerol nanostructured lipid carriers sustained release bioavailability 



The authors also thank the University Ethics Committee for the kind guidance in the animal experiments.


This work was supported by National Natural Science Foundation of China (81473172, 81503025, 81720108030 and 81773695), National “Twelfth Five-Year” Plan for Science & Technology Support (Grant 2013BAD16B07-1), Special Funds for 333 and 331 projects (BRA2013198), Industry-University-Research Institution Cooperation (JHB2012-37, GY2013055) in Jiangsu Province and Zhenjiang City, Program for Scientific Research Innovation Team in Colleges and Universities of Jiangsu Province (SJK-2015-4), and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

Compliance with Ethical Standards

Healthy male Sprague-Dawley rats were obtained from Experimental Animal Center of Jiangsu University (Zhenjiang, China), and the in vivo experimental procedures all abided by the ethics and regulations of animal experiments approved by the Ethic Committee of Jiangsu University.

Conflict of Interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Ghosh AK, Banerjee S, Mullick HI, Banerjee J. Zingiber officinale: a natural gold. Int J Pharma Bio Sci. 2011;2:283–94.Google Scholar
  2. 2.
    Zick SM, Ruffin MT, Djuric Z, Normolle D, Brenner DE. Quantitation of 6-, 8- and 10-Gingerols and 6-Shogaol in human plasma by high-performance liquid chromatography with electrochemical detection. Int J Biomed Sci. 2010;6:233–40.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Kim JS, Lee SI, Park HW, Yang JH, Shin TY, Kim YC, et al. Cytotoxic components from the dried rhizomes of Zingiber officinale roscoe. Arch Pharm Res. 2008;31:415–8. Scholar
  4. 4.
    An KJ, Zhao DD, Wang ZF, Wu JJ, Xu YJ, Xiao GS. Comparison of different drying methods on Chinese ginger (Zingiber officinale roscoe): changes in volatiles, chemical profile, antioxidant properties, and microstructure. Food Chem. 2016;197:1292–300. Scholar
  5. 5.
    Wu H, Horng C, Tsai S, Lee Y, Hsu S, Tsai Y, et al. Relaxant and vasoprotective effects of ginger extracts on porcine coronary arteries. Int J of Mol Med. 2018;41(4):2420–8. Scholar
  6. 6.
    Semwal RB, Semwal DK, Combrinck S, Viljoen AM. Gingerols and Shogaols: important nutraceutical principles from ginger. Phytochemistry. 2015;117:554–68. Scholar
  7. 7.
    Feng X, Kong W, Wei J, Ou-Yang Z, Yang M. HPLC fingerprint analysis combined with chemometrics for pattern recognition of ginger. Pharm Biol. 2014;52:362–7. Scholar
  8. 8.
    Nile S, Park S. Chromatographic analysis, antioxidant, anti-inflammatory, and xanthine oxidase inhibitory activities of ginger extracts and its reference compounds. Ind Crop Prod. 2015;70:238–44. Scholar
  9. 9.
    Yang MQ, Ye LL, Liu XL, Qi XM, Lv JD, Wang G, et al. Gingerol activates noxious cold ion channel TRPA1 in gastrointestinal tract. Chin J Nat Med. 2016;14:434–40. Scholar
  10. 10.
    Singh AB, Akanksha, Singh N, Maurya R, Srivastava AK. Anti-hyperglycaemic, lipid lowering and anti-oxidant properties of [6]-gingerol in db/db mice. Int J Med Med Sci. 2009;1:536–44.Google Scholar
  11. 11.
    Tzeng TF, Chang CJ, Liu IM. 6-Gingerol inhibits rosiglitazone-induced adipogenesis in 3T3-L1 adipocytes. Phytother Res. 2014;28:187–92. Scholar
  12. 12.
    Young HY, Luo YL, Cheng HY, Hsieh WC, Liao JC, Peng WH. Analgesic and anti-inflammatory activities of [6]-gingerol. J Ethnopharmacol. 2005;96:207–10. Scholar
  13. 13.
    Almada da Silva J, Becceneri AB, Sanches Mutti H, Martin A, Silva M, Fernandes J, et al. Purification and differential biological effects of ginger-derived substances on normal and tumor cell lines. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;903:157–62. Scholar
  14. 14.
    Rodrigues F, Prata M, Oliveira I, Alves N, Freitas R, Monteiro H, et al. Gingerol fraction from Zingiber officinale protects against gentamicin-induced nephrotoxicity. Antimicrob Agents Chemother. 2014;58:1872–8. Scholar
  15. 15.
    Sabina E, Pragasam S, Kumar S, Rasool M. 6-Gingerol an active ingredient of ginger, protects acetaminophen-induced hepatotoxicity in mice. J Chin Integr Med. 2011;9:1264–9. Scholar
  16. 16.
    Bhattarai S, Tran V, Duke C. Stability of [6]-gingerol and [6]-shogaol in simulated gastric and intestinal fluids. J Pharm Biomed Anal. 2007;45:648–53. Scholar
  17. 17.
    Jiang SZ, Wang NS, Mi SQ. Plasma pharmacokinetics and tissue distribution of [6]-gingerol in rats. Biopharm Drug Dispos. 2008;29:529–37. Scholar
  18. 18.
    Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine. 2015;12:143–61. Scholar
  19. 19.
    Shi F, Wei Z, Zhao Y, Xu X. Nanostructured lipid carriers loaded with Baicalin: an efficient carrier for enhanced antidiabetic effects. Pharmacogn Mag. 2016;12(47):198–202. Scholar
  20. 20.
    Souto E, Almeida A, Müller R. Lipid nanoparticles (SLN®, NLC®) for cutaneous drug delivery: structure, protection and skin effects. J Biomed Nanotechnol. 2007;3:317–31. Scholar
  21. 21.
    Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol. 2013;7:41–55. Scholar
  22. 22.
    Aditya N, Macedo A, Doktorovova S, Souto E, Kim S, Chang P, et al. Development and evaluation of lipid nanocarriers for quercetin delivery: a comparative study of solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and lipid nanoemulsions (LNE). LWT-Food Sci Technol. 2014;59:115–21. Scholar
  23. 23.
    Liu Y, Wang L, Zhao Y, He M, Zhang X, Niu M. Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin. Int J Pharm. 2014;476:169–77. Scholar
  24. 24.
    Yuan L, Liu C, Chen Y, Zhang Z, Zhou L, Qu D. Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model. Int J Nanomedicine. 2013;8:4339. Scholar
  25. 25.
    Wang F, Chen L, Zhang D, Jiang S, Shi K, Huang Y, et al. Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study. J Drug Target. 2014;22(9):849–58. Scholar
  26. 26.
    Weiss J, Decker EA, Mcclements DJ, Kristbergsson K, Helgason T, Awad T. Solid lipid nanoparticles as delivery systems for bioactive food components. Food Biophys. 2008;3:146–54. Scholar
  27. 27.
    Karn-orachai K, Smith SM, Phunpee S, Treethong A, Puttipipatkhachorn S, Pratontep S, et al. The effect of surfactant composition on the chemical and structural properties of nanostructured lipid carriers. J Microencapsul. 2014;31:609–18. Scholar
  28. 28.
    Ferreira M, Chaves LL, Lima SA, Reis S. Optimization of nanostructured lipid carriers loaded with methotrexate: a tool for inflammatory and cancer therapy. Int J Pharm. 2015;492:65–72. Scholar
  29. 29.
    Zhang M, Viennois E, Prasad M, Zhang Y, Wang L, Zhang Z, et al. Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials. 2016;101:321–40. Scholar
  30. 30.
    Manatunga D, Silva R, Silva K, Silva N, Bhandari S, Yap Y, et al. pH responsive controlled release of anti-cancer hydrophobic drugs from sodium alginate and hydroxyapatite bi-coated iron oxide nanoparticles. Eur J Pharm Biopharm. 2017;117:29–38. Scholar
  31. 31.
    Xu Y, Wang QL, Feng YS, Firempong CK, Zhu Y, Omari-Siaw E, et al. Enhanced oral bioavailability of [6]-Gingerol-SMEDDS: preparation, in vitro and in vivo evaluation. J Funct Foods. 2016;27:703–10. Scholar
  32. 32.
    Wang QL, Wei QY, Yang QX, Cao X, Li Q, Shi F, et al. A novel formulation of [6]-gingerol: Proliposomes with enhanced oral bioavailability and antitumor effect. Int J Pharm. 2018;535:308–15. Scholar
  33. 33.
    Rosli NA, Hasham R, Aziz AA, Noor NM, & Aziz RA Formulation and characterization of [6]-Gingerol loaded nanostructured lipid carrier (NLC). International Science Postgraduate Conference 2014.Google Scholar
  34. 34.
    Shi F, Zhao YY, Firempong CK, Xu XM. Preparation, characterization and pharmacokinetic studies of linalool-loaded nanostructured lipid carriers. Pharm Biol. 2016;54:2320–8. Scholar
  35. 35.
    Zhuang CY, Li N, Wang M, Zhang XN, Pan WS, Peng JJ, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm. 2010;394:179–85. Scholar
  36. 36.
    Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces. 2011;85:262–9. Scholar
  37. 37.
    Yang Y, Corona A, Schubert B, Reeder R, Henson M. The effect of oil type on the aggregation stability of nanostructured lipid carriers. J Colloid Interface Sci. 2014;418:261–72. Scholar
  38. 38.
    Chu C, Tong S, Xu Y, Wang L, Fu M, Ge Y, et al. Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo. Acta Pharmacol Sin. 2011;32:973–80. Scholar
  39. 39.
    Wang Y, Wang S, Firempong CK, Zhang H, Wang M, Zhang Y, et al. Enhanced solubility and bioavailability of naringenin via liposomal nanoformulation: preparation and in vitro and in vivo evaluations. AAPS PharmSciTech. 2016;18:586–94. Scholar
  40. 40.
    Li H, Chen M, Su Z, Sun MJ, Ping Q. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery. Int J Pharm. 2016;511:524–37. Scholar
  41. 41.
    Jia L, Shen J, Zhang D, Duan C, Liu G, Zheng D, et al. In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. Int J Biol Macromol. 2012;50:523–9. Scholar
  42. 42.
    Wang W, Chen L, Huang X, Shao A. Preparation and characterization of minoxidil loaded nanostructured lipid carriers. AAPS PharmSciTech. 2017;18(2):509–16. Scholar
  43. 43.
    Ni S, Sun R, Zhao G, Xia Q. Quercetin loaded nanostructured lipid carrier for food fortification: preparation, characterization and in vitro study. J Food Process Eng. 2014;38:93–106. Scholar
  44. 44.
    Tran T, Ramasamy T, Truong D, Choi H, Yong C, Kim J. Preparation and characterization of Fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. AAPS PharmSciTech. 2014;15(6):1509–15. Scholar
  45. 45.
    Zhu Y, Wang M, Zhang J, Peng W, Firempong CK, Deng W, et al. Improved oral bioavailability of capsaicin via liposomal nanoformulation: preparation, in vitro drug release and pharmacokinetics in rats. Arch Pharm Res. 2015;38:512–21. Scholar
  46. 46.
    Feng Y, Sun C, Yuan Y, Zhu Y, Wan J, Firempong CK, et al. Enhanced oral bioavailability and in vivo antioxidant activity of chlorogenic acid via liposomal formulation. Int J Pharm. 2016;501(1–2):342–9. Scholar
  47. 47.
    Luan J, Zheng F, Yang X, Yu A, Zhai G. Nanostructured lipid carriers for oral delivery of baicalin: In vitro and in vivo evaluation. Colloid Surface A. 2015;466:154–9. Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  1. 1.Department of Pharmaceutics, School of Pharmacy, Center for Nano Drug/Gene Delivery and Tissue EngineeringJiangsu UniversityZhenjiang CityChina

Personalised recommendations